

Hypothesis

Not peer-reviewed version

The Neuromodulatory Fragility Hypothesis of Alzheimer's Disease Pathogenesis

[Alfie Wearn](#)^{*}, Kate M. Onuska, Taylor W. Schmitz, Gary R. Turner, R. Nathan Spreng

Posted Date: 11 February 2026

doi: 10.20944/preprints202512.0510.v2

Keywords: neuromodulatory fragility hypothesis; neuromodulatory subcortical systems; Alzheimer's disease; pathogenesis; neuronal vulnerability; risk factors; neuronal resilience; b-amyloid; tau; neuroinflammation; noradrenaline; acetylcholine; serotonin; dopamine; orexin



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Hypothesis

The Neuromodulatory Fragility Hypothesis of Alzheimer's Disease Pathogenesis

Alfie Wearn ^{1,*}, Kate M. Onuska ¹, Taylor W. Schmitz ², Gary R. Turner ³
and R. Nathan Spreng ^{1,4,5,6}

¹ Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, QC, Canada

² Department of Physiology & Pharmacology, Western Institute for Neuroscience, Western University, London, N6A 5C1, ON, Canada

³ Department of Psychology, York University, Toronto, M3J 1P3, ON, Canada

⁴ McConnell Brain Imaging Centre, McGill University, Montreal, H3A 2B4, QC, Canada

⁵ Douglas Mental Health University Institute—Research Center, Verdun, H4H 1R3, QC, Canada

⁶ Department of Psychiatry, McGill University, Montreal, H3A 1A1, QC, Canada

* Correspondence: alfie.wearn@mcgill.ca

Abstract

Sporadic Alzheimer's disease (AD) is associated with numerous risk factors, yet its precise cause remains unclear. Here, we describe a novel framework for AD pathogenesis, whereby diverse risk factors converge on neuromodulatory subcortical systems to confer AD risk or resilience. Neuromodulatory projection neurons are uniquely fragile due to their large size, sparse myelination, and high basal metabolic demands. We propose that the increased prevalence of AD in older adult populations likely reflects a universal weakness within these projection systems, which is increasingly exposed as cellular transport and maintenance mechanisms deteriorate with age. The key insight of this '*neuromodulatory fragility hypothesis*' is that neuromodulatory system dysfunction is sufficient to explain both tau hyperphosphorylation and β -amyloid ($A\beta$) plaque formation, the two pathological hallmarks of AD. We therefore predict that strengthening or preserving the endogenous functions of these systems in midlife represents the most effective strategy for preventing AD.

Keywords: neuromodulatory subcortical systems; Alzheimer's disease; pathogenesis; neuronal vulnerability; risk factors; neuronal resilience; β -amyloid; tau; neuroinflammation; noradrenaline; acetylcholine; serotonin; dopamine; orexin

1. Introduction: What Causes Alzheimer's Disease?

Identifying the cause of Alzheimer's disease (AD) remains one of the most urgent challenges in modern medicine, yet its complexity continues to preclude a single parsimonious explanation of pathogenesis[1]. Many risk factors have been identified, which combine and interact to confer relative risk or resilience[2]. These include age, genetics, traumatic brain injury, comorbidities, physical inactivity, sleep disruption, viral or bacterial infection, among others[1,2]. The diversity of these 'causes' contrasts sharply with the relatively uniform sequence of pathological events that define AD. While individual progression patterns and clinical presentations can vary[3,4] (discussed in section 8), AD typically unfolds in the brain as follows: tau neurofibrillary tangles and pre-tangles spread according to *Braak* stages[5], β -amyloid ($A\beta$) plaques emerge according to *Thal* stages[6], and subsequent tau-associated neurodegeneration drives canonical patterns of cognitive decline, ultimately leading to dementia[7]. A system whereby varied causes lead to relatively uniform outcomes implies the existence of a single upstream vulnerability: a common breakpoint where diverse insults converge to initiate a pathological cascade (Postulate 1, Box 1). Furthermore, by Occam's razor, a single breakpoint is much more likely an explanation of pathogenesis than multiple

simultaneously dysfunctioning systems (Postulate 2, Box 1). This is especially true in a disorder as common as AD, which affects a third of people over the age of 85[8]. There is, therefore, a need for explanations of AD pathogenesis that unify the emergence of both A β and tau pathology under a single cause. Finally, given the high prevalence of AD, the single breakpoint is likely a feature of normal brain architecture rather than an obscure abnormality (Postulate 3, Box 1). Identification of this breakpoint is critical, as its protection would provide the most effective option for disease prevention[9].

Box 1. Postulates of the *neuromodulatory fragility hypothesis* of AD pathogenesis.

- Postulate 1: Diverse causes leading to (relatively) uniform outcomes suggests a single upstream vulnerability.
- Postulate 2: A single breakpoint is a simpler explanation of pathogenesis than multiple breakpoints, especially in an extremely common disorder (Occam’s Razor)
- Postulate 3: In an extremely prevalent disorder (like AD), the breakpoint is more likely a feature of normal brain architecture than an obscure abnormality
- Neuromodulatory subcortical projection neurons, specifically their tau-rich axonal terminals, are a prime candidate for this single vulnerable breakpoint. Multiple risk factors can converge on this system to confer risk of AD. Variation across individuals in neuromodulatory resilience is a likely predictor of relative risk for AD.

We argue that neuromodulatory subcortical projection neurons represent a prime candidate for this vulnerable breakpoint. These neurons are uniquely fragile: their large, sparsely myelinated, tau-rich axons have extraordinary energy demands, making them highly dependent on a steady supply of resources and fully functional repair mechanisms[10,11]. We propose that the heightened prevalence of AD among older adults therefore reflects a universal weakness within these projection systems, which is increasingly exposed in older age when cellular transport and maintenance mechanisms falter[12,13]. In a sentence: we believe that it is no coincidence that the hardest-to-maintain parts of the most fragile neurons are enriched for a pre-pathogenic component (tau) of the most common cause of dementia worldwide.

We propose the following mechanistic framework whereby AD, from its earliest pathogenesis to clinical dementia, can be understood as a downstream consequence of neuromodulatory fragility (Figure 1). Declining metabolic efficiency and impaired cellular transport and clearance mechanisms in advancing age disproportionately affect these cells, particularly in tau-rich axons extremely distal from the cell nucleus. Accumulated oxidative stress drives tau hyperphosphorylation and misfolding, leading to axonal instability and reduced neuromodulatory tone at cortical endpoints. This loss of neuromodulatory input disrupts microglial homeostasis and impairs the clearance of early A β species, eventually leading to plaque formation. Misfolded, hyperphosphorylated tau spreads slowly and transneuronally through highly active networks, while A β plaques continue to form across the cortex. Eventual local interactions of A β and tau pathology accelerate the activity-dependent transneuronal spread of tau due to A β -induced hyperexcitability, culminating in widespread neurodegeneration and dementia onset.

In this perspective paper we describe this *neuromodulatory fragility hypothesis* of AD pathogenesis in more detail, describing a broad view of the entire AD process from pathogenesis to dementia onset. The framework this hypothesis provides shifts the focus from late-stage cortical hallmarks to vulnerable subcortical origins which become dysfunctional long before the clinical manifestation of the disease. The framework situates sporadic AD as a disorder of statistical vulnerability rather than a singular initiating insult *per se*. In lieu of refuting the amyloid hypothesis, which has dominated thinking and research on AD for more than 30 years[14], we suggest a reframing, whereby A β accumulation may be a downstream consequence of a fundamental dysfunction of neuromodulatory subcortical projection neurons, rather than the initiating trigger of sporadic AD pathogenesis. By viewing AD through the lens of neuromodulatory fragility, we can integrate disparate findings on

tau seeding, the neuroinflammatory response and nebulous prodromal behavioural changes into a unified theory of AD pathogenesis.




Figure 1. Flowchart of the proposed neuromodulatory fragility hypothesis of AD pathogenesis. Risk factors confer vulnerability or resilience to neuromodulatory subcortical systems (NSS) either directly or indirectly through disproportionate consequences in whole brain health. Due to disruptions in cell maintenance in distal axons, tau becomes hyperphosphorylated and misfolded, causing axonal instability and reduced cortical neuromodulatory tone. This causes nebulous early symptoms (sleep disruption, mood instability, attention deficits) and disrupts microglial homeostasis, impairing amyloid clearance. Misfolded tau spreads transneuronally from NSS cells, while A β appears in increasingly widespread cognitive regions. When A β and tau interact (typically in inferior temporal cortex), tau spread, and associated neurodegeneration are exacerbated, and cognition declines rapidly, eventually leading to dementia.

2. Neuromodulatory Projection Neurons Are a System-Wide Weak Point

Neuromodulatory subcortical systems can be analogised as the conductors to the orchestra of the brain. Where glutamatergic and GABA-ergic neurons facilitate the bulk of the brain’s activity (the orchestra), dramatically smaller populations of neuromodulatory neurons (the conductors) shape the dynamics and characteristics of their combined activity[15,16]. These systems release neurotransmitters such as noradrenaline, acetylcholine, dopamine, serotonin, and orexin. Given their pivotal role in modulating brain activity, these neuromodulators are implicated in many fundamental cognitive and behavioural processes including regulating sleep-wake cycles, mood stability, attention, appetite control, even interacting with the brain’s immune system[17–22].

A key distinction between neuromodulatory neurons and other projection neurons is their use of ‘volume transmission’: they can release neurotransmitters from varicosities along the axon into the extracellular space without a specific postsynaptic target, in addition to classical synaptic release[23]. Several anatomical and physiological features simultaneously enable this mode of signalling while simultaneously heightening their fragility:

- 1) **Extreme axonal length and arborization:** The projection neurons of neuromodulatory systems originate from small clusters of cell bodies (e.g. locus coeruleus, nucleus basalis of Meynert, dorsal raphe, ventral tegmental area, lateral hypothalamus), yet send vast, highly arborized projections across the entire neocortex. The extreme length and breadth of these combined arborizations allows each neuron to modulate large areas[24–26]. However, maintaining such long, branched projections is metabolically expensive. These systems require continuous transport of proteins, mitochondria and other cellular components, rendering them chronically dependent on nutrients, growth factors and oxygen, as well as effective waste clearance and repair mechanisms[27,28].
- 2) **High tonic firing rates:** To sustain basal neuromodulatory tone over large target areas, neuromodulatory neurons exhibit high tonic firing rates, with regular transient bursts during behaviourally relevant events[29–32]. This firing pattern is well-suited to facilitate slow, diffuse

modulation via volume transmission, but further amplifies metabolic demand, increasing susceptibility to any disruption in oxidative balance, calcium homeostasis or energy production.

- 3) **Poor myelination.** Neuromodulatory axons are typically thin and only sparsely myelinated. This facilitates 'leakiness' of neurotransmitter along the axon's length – the definitive feature of 'volume transmission'. However, the lack of myelination and thin calibre of these neurons offers little protection against oxidative or mechanical injury[33,34]. Cortical regions with higher myelination are relatively resistant to pathology and neurodegeneration, suggesting that myelin may represent a substrate of 'brain reserve' that these projection systems largely lack[34,35]. The constant axonal remodelling that may be required to maintain these delicate projections could further exacerbate the metabolic demands of these systems.

Taken together, the features that allow neuromodulatory systems to modulate large-scale brain states (extreme arborization, high tonic activity, poor myelination) also impose high energetic demands, low tolerance for metabolic and oxidative stress and a strong propensity to accumulate damage over the lifespan. The fact that these same features are essential for their function helps explain the apparent evolutionary maladaptiveness of these features: typical evolutionary routes to increase resilience, such as increasing myelination or pruning excess branches, would directly impair their modulatory capacity and are therefore unlikely to be favoured by natural selection.

Aging, the primary risk factor for sporadic AD, is poised to disproportionately affect these low-tolerance systems through changes such as mitochondrial dysfunction, oxidative stress and disrupted calcium homeostasis[11,12,36]. Monoaminergic neurons are particularly at-risk for oxidative stress. By-products of noradrenaline and dopamine synthesis generate reactive oxygen species throughout life, particularly in axons and terminals where these neurotransmitters are produced[37]. Neuromelanin, a compound found in monoaminergic neurons, normally sequesters these toxic metabolites, but when its capacity is reached in older age, intracellular toxicity rises sharply, possibly marking a transition from resilience to degeneration[38]. In cholinergic neurons, age-related reductions in calcium-binding proteins increase their susceptibility to calcium-induced excitotoxicity and pathological processes[39]. Aging therefore imposes a critical bottleneck on these inherently fragile neuronal systems.

Other risk factors for AD likely modulate the vulnerability of neuromodulatory projection neurons, either through specific direct mechanisms or through systemic changes to brain health. Take as an example the apolipoprotein E- $\epsilon 4$ (*APOE4*) gene, the single largest genetic risk factor for sporadic AD. Carriers of one or two *APOE4* alleles face up to 3- or 15-fold greater risk, respectively, than *APOE3* homozygotes[40]. *APOE4* is thought to impair myelin regulation[41]. It is feasible that myelin dysregulation would disproportionately increase the vulnerability of neuromodulatory projection neurons which already lack robust myelination and therefore have little to no redundancy on which to fall back. In effect, we propose that what little protection these neurons have under an *APOE3* genotype is weakened or lost with an *APOE4* genotype, further destabilizing an already fragile system. The inverse may well be true of the neuroprotective *APOE2* allele. This framework aligns with evidence of selective neuromodulatory system damage in demyelinating conditions such as multiple sclerosis and encephalomyelitis[42].

We have so far explained how upstream risk factors converge onto neuromodulatory systems to cause disproportionate dysfunction. The next sections will explain how this dysfunction is sufficient to explain the downstream emergence of the A β and tau pathology which define AD.

3. Tau Hyperphosphorylation Is a Direct Outcome of Neuromodulatory System Disruption

Tau is a protein that binds and stabilizes microtubules, supporting axonal structure[43]. In the highly arborized projection neurons of neuromodulatory systems, axons are extremely distal from the cell nucleus[24–26]. This makes their axonal machinery, of which physiological tau is a key component, particularly susceptible to disruptions in transport, repair and clearance processes[44–

46]. In other words, these axons, especially distal, tau-rich regions, are the most vulnerable part of an already fragile system (Figure 2).




Figure 2. Schematic depiction of the emergence of Aβ plaques and tau tangles due to neuromodulatory dysfunction. The left image depicts a healthy neuromodulatory projection system with good neuromodulatory tone across the entire neocortex. The middle panel depicts the emergence of tau dysfunction due to the convergence of lifetime-accumulated risk factors. This dysfunction (shown in red) occurs first in the most distal, and therefore most vulnerable, branches of the axonal tree. The image also depicts the emergence of tau tangles in the cell bodies. The right panel shows how regions where tau was disrupted become destabilised and dysfunctional (depicted by thin grey lines in the place of red areas in middle panel). This instability gives rise to reduced neuromodulatory tone, microglial dysregulation and impaired clearance of Aβ oligomers, resulting in the emergence of Aβ plaques. At this stage, tau tangles are abundant in the neuromodulatory neuron cell bodies.

Reliable clearance of reactive oxygen species from these distal structures is particularly critical. When reactive oxygen species accumulate (e.g. as by-products of the monoaminergic synthesis pathway[38,47]), oxidative stress triggers tau hyperphosphorylation, producing misfolded forms of tau that can no longer bind microtubules[48]. The result is axonal instability, disrupted intracellular transport and impaired neurotransmission[44,45].

Misfolded oligomers of hyperphosphorylated tau cluster together to form neurofibrillary tangles, which are first detectable in neuromodulatory nuclei in presymptomatic AD[10,49]. Tau tangles are reported as early as the second decade of life in the locus coeruleus[18,50], and the third decade of life in the nucleus basalis of Meynert[51]. Tangles have also been found in orexinergic neurons of the lateral hypothalamus[52] and serotonergic dorsal raphe neurons[53,54] in presymptomatic AD. In the locus coeruleus and basal forebrain, hyperphosphorylated tau species have been shown to lead to decreased fibre density and reduced neuromodulatory tone[48,55].

A growing body of evidence supports the idea that tau pathology spreads transneuronally in an activity-dependent manner, progressing most rapidly along densely connected pathways[56,57]. Early propagation likely occurs between neuromodulatory nuclei themselves, given their extensive inter-connectivity, which complicates efforts to identify the precise initial locus of pathology in population-based studies. Strong connections between these nuclei and cortical sites of early tau pathology in AD, together with evidence that tau pathology and atrophy in neuromodulatory nuclei precede corresponding changes in medial temporal regions[58–62], have led to the proposal that tau advances from subcortical hubs to the medial temporal lobe and beyond, following canonical Braak staging[5]. Under the *neuromodulatory fragility hypothesis*, neuromodulatory nuclei act as seed points, propagating tau pathology to densely connected efferents to initiate cortical pathology. While tau

accumulation in these early stages causes local neurodegeneration, the extent of spread and, by extension, overt clinical symptoms remain limited until the process is amplified by A β pathology (described in section 5)[63].

4. Neuromodulatory System Degradation Disrupts A β Clearance Through Neuroinflammatory Pathways

Interactions between neuromodulatory systems and A β are less well characterised than those with tau. The link is perhaps less obvious as A β plaques rarely accumulate around neuromodulatory cell bodies until relatively late stages of AD, typically *Thal* stage five[6]. Nevertheless, several mechanisms suggest that neuromodulatory system dysfunction could underlie the emergence of A β pathology.

As tau hyperphosphorylation destabilises the axons of neuromodulatory projections, distal axons degenerate, and cortical neuromodulatory tone declines[64] (Figure 2). Reduced neuromodulatory tone leads to the release of pro-inflammatory cytokines and microglial dysregulation, which, in turn, impairs A β clearance[65–68]. Experimentally induced degeneration of cholinergic and noradrenergic subcortical systems in animal models leads to A β plaque accumulation[65,69]. Conversely, replacement or receptor-agonist treatment can reverse these downstream effects, supporting a causal role for neuromodulatory dysfunction in promoting A β deposition[70,71]. While most direct evidence for the neuroinflammation-mediated dysregulation of A β clearance concerns the noradrenergic and cholinergic systems, similar anti-inflammatory and neuroprotective properties have been observed for orexin[72].

Neuromodulatory neurons may also contribute directly to early A β seeding. Both noradrenergic and cholinergic subcortical neurons have been shown to accumulate intracellular A β oligomer species in neurites and axon terminals[73,74]. Furthermore, noradrenaline may directly facilitate amyloidogenic processing of the amyloid precursor protein[75,76]. When clearance mechanisms are performing optimally, early A β species have little chance to cluster into plaques. However, once microglial dysfunction arises, A β fails to be cleared, and may therefore act as an initial seed that facilitates A β plaque formation, as described above. A β species may also induce or exacerbate hyperexcitability of neuromodulatory systems[77], which is likely to cause further metabolic strain and oxidative stress, augmenting downstream pathological processes.

In contrast to the transneuronal spread of tau, A β plaque formation appears wherever distal neuromodulatory tone is depleted. As with leaves falling from an autumn tree, the exact branch to lose foliage first may differ between individuals of even similar trees, but loss is inevitable once environmental conditions shift, and the tree restricts nutrients to more proximal regions. This analogy aligns with the observed interindividual variability in A β plaque localisation in early *Thal* stages[6], despite the high prevalence of A β among even cognitively unimpaired older adult populations[78].

Neuroinflammation is a critical but poorly understood element of AD, often debated as either a cause, effect or epiphenomenon of the disease process. The *neuromodulatory fragility hypothesis* highlights a specific role for neuroinflammation in triggering and amplifying spread of A β pathology. The positive feedback loops by which neuroinflammation shifts from neuroprotection to neurotoxicity amplify the difficulty of studying the exact causative role of neuroinflammation in AD. Our model clarifies the sequence of events, which will aid generation of specific testable hypotheses to better understand this complex relationship.

5. Tau Misfolding Precedes Plaque Accumulation But Is Slow in the Absence of A β

Neurodegeneration and symptom onset correlate more strongly with tau neurofibrillary tangles than with A β pathology[79]. However, in the absence of A β , tau-associated toxicity, behavioural impairments and the spatial extent of tau are greatly attenuated in AD[80]. This latter detail likely

reflects the interaction of two key mechanisms driven by the AD hallmarks: A β causes neuronal hyperexcitability, and tau spreads transneuronally in an activity-dependent manner[63,81].

In our *neuromodulatory fragility hypothesis* of AD pathogenesis, tau misfolding originates in neuromodulatory projection neurons and spreads slowly along dense, highly active pathways, most notably projecting from neuromodulatory nuclei to the medial temporal lobe. In the absence of A β , as in primary age-related tauopathy, tau remains spatially restricted but still colocalizes with neurodegeneration[82]. In AD, as both tau and A β pathologies spread, they eventually converge. At this convergence point, significant A β -driven neuronal hyperexcitability amplifies transneuronal tau propagation, driving rapid global distribution of tau. Graph theory and network modelling studies support this model, identifying the inferior temporal lobe as the most common site of A β -tau colocalization[83,84]. This colocalization and subsequent increasing rate of tau propagation is likely the tipping point between presymptomatic and symptomatic disease.

Because tau spread and symptom severity depend on A β pathology, A β is sometimes regarded as an 'upstream' disease feature relative to altered tau proteostasis[80]. However, our model positions tau dysregulation as the earliest molecular consequence of neuromodulatory system failure, preceding A β pathology. These seemingly contradictory views are reconcilable when considered across scales. With a traditional systems-level view of disease, focusing on clinical symptom onset, A β moderates the spread and severity of tau pathology, and hence is considered 'upstream'[80,81]. However, as we have described in the previous sections, at the cellular level, resource disruption in fragile neuromodulatory systems provides the initiating conditions that trigger tau misprocessing, which is sufficient to explain A β accumulation through microglial dysregulation[45,48,64,65]. It is clear that these views are not in fact contradictory, rather, they prioritise different scales at which the term 'upstream' is defined. The idea that tau misfolding precedes that of A β is not new, but the two processes are typically regarded as independent inciting events[85,86]. In contrast, our framework positions neuromodulatory fragility as a single upstream cause for both.

In humans, A β and tau interact continuously throughout AD. Pathogenic tau species can promote A β deposition (as discussed above), while A β may directly augment tau hyperphosphorylation e.g. through GSK-3 β signalling[37]. Direct injection of A β can initiate tau pathology in rodent models expressing mutant human tau[87], but we argue that this injection 'skips ahead' in the usual pathological progression, bypassing the neuromodulatory dysfunction-associated altered tau proteostasis and triggering the positive feedback loop from an alternate entry point. In other words, this rodent model, while useful for studying downstream stages of the disease, does not recapitulate natural pathogenesis of sporadic AD.

This mechanism may, however, align with pathogenesis in autosomal dominant AD. Autosomal dominant AD is a rare genetic form of AD characterized by early symptom onset, and is caused by mutations in three genes which directly affect the A β pathway[88]. While the clinical presentation and late-stage pathology of sporadic AD vs autosomal dominant AD are very similar, it remains unclear to what extent their upstream mechanisms of pathogenesis differ. We speculate that the intrinsic fragility of neuromodulatory projection neurons is a shared feature of pathogenesis in both cases, with differences arising in the balance and timing of misfolded A β and tau species. Indeed, early vulnerability of noradrenergic[89,90], cholinergic[91] (but see[92]) and serotonergic[93] systems has been demonstrated in individuals carrying autosomal dominant AD mutations. We propose that whereas in sporadic late-onset AD, toxic A β oligomers are efficiently cleared until older age (e.g. by proteases and microglia), autosomal dominant AD mutations create conditions of chronic A β overproduction or impaired clearance that overwhelm these mechanisms much earlier in life, effectively ensuring earlier onset of the same neuromodulatory fragility-driven cascade.

In our *neuromodulatory fragility hypothesis*, we highlight how a single point of fragility can trigger a self-perpetuating state of pathology. Closely interacting factors can rapidly obscure the direction of cause-effect relationships in experimental settings. Mechanistic explanations such as those presented here by the *neuromodulatory fragility hypothesis* are therefore crucial for forming effective research questions and hypotheses aimed at disentangling these relationships.

6. Early Behavioural Symptoms Are Consistent with Early Neuromodulatory Dysfunction

We acknowledge that compensatory mechanisms (potentially within these neuromodulatory systems) maintain near-normal cognitive functioning for many years, despite concurrent pathophysiological processes[94]. Thus, clinically detectable symptoms most likely emerge as these mechanisms reach their limits and begin to fail. In AD, an episodic memory deficit is the most definitive and clinically recognised early symptom, however patients often report symptoms months or years before measurable memory impairment[95]. These subtle perturbations in cognition and behaviour align closely with a model of early neuromodulatory system dysfunction, including: dysregulation of sleep-wake cycles (orexin, noradrenaline), attention deficits (acetylcholine, noradrenaline) and mood instability (serotonin)[10,95]. The emergence of neuropsychiatric symptoms in later disease stages likely reflects a more substantial breakdown of global neuromodulatory control[96].

7. Predictions of the Neuromodulatory Fragility Hypothesis

The proposed framework makes several testable predictions about AD that could guide future research. A key prediction of the hypothesis is that enhancing the resilience of neuromodulatory systems should significantly delay or prevent the onset of AD. Strengthening these systems, through interventions that reduce oxidative stress or support intracellular transport and repair, could slow or halt early pathogenesis if applied early enough. Rather than proposing a single ‘cure-all’ mechanism, this framework aligns with existing evidence on the importance of modifiable risk factors such as cardiovascular health, sleep regulation, and protection from head injury as effective preventive strategies in midlife[2]. That said, a theoretical pharmacological augmentation of neuromodulatory resilience would provide effective targeted AD protection[9].

The *neuromodulatory fragility hypothesis* also predicts that accurate tracking of neuromodulatory system health could improve early detection and monitoring of disease progression. Recent advances in neuroimaging, including quantitative and neuromelanin-sensitive MRI, ultra-high-field diffusion imaging and positron emission tomography, have improved *in vivo* assessment of these systems[97–99]. As these tools mature and become more widely available, clinical monitoring of neuromodulatory integrity may become feasible for early diagnosis and therapeutic evaluation.

An additional implication of the model concerns the limited efficacy of anti-A β treatments, especially if applied late in the disease process[85]. Once cortical A β burden is high, positive feedback loops characteristic of AD are already established, and the spreading of tau pathology is already well underway. Removing A β at this stage may modestly slow disease progression but is unlikely to halt it. While even incremental slowing of disease remains valuable (if side-effects can be minimized) we argue that therapies targeting patients who are already A β -positive may miss the critical early window of intervention. According to the *neuromodulatory fragility hypothesis*, A β is positioned as an important but downstream element of AD pathology, while preventing or mitigating neuromodulatory dysfunction offers a more promising means of arresting AD progression.

8. Unanswered Questions

While the *neuromodulatory fragility hypothesis* ties together many known features of the AD trajectory, several questions remain open and warrant further investigation.

One such question concerns atypical subtypes of AD. It is becoming increasingly apparent that although progression patterns of tau are often categorised into canonical Braak stages, there is evidence for multiple subtypes of tau progression pattern, each with subtly different characteristics in terms of severity, topography, speed of progression and behavioural presentation[3,4]. It remains unclear whether all AD subtypes share the same underlying aetiology. Tau transmission along neuromodulatory projection pathways may follow probabilistic routes that vary across individuals leading to different clinical and anatomical presentations. Alternatively, different subtypes might

arise from dysfunction in distinct neuromodulatory systems or through entirely separate mechanisms.

A related question is whether all neuromodulatory systems are equally vulnerable or whether specific nuclei are consistently affected first. If the latter is true, targeted strategies to augment resilience of a given, particularly vulnerable, neuromodulatory system could be highly effective. Alternatively, neuromodulatory systems may be strongly interdependent, and dysfunction in any one of a few candidate systems may be swiftly transmitted to others, necessitating a broader therapeutic strategy.

Additionally, while we have proposed that environmental and demographic factors confer risk of AD through their impact on neuromodulatory systems, the specific underlying mechanisms remain poorly understood. For example, AD is more prevalent in women, possibly reflecting menopause-related neuroendocrine changes that increase neuromodulatory fragility[100]. Likewise, differences in disease incidence and clinical presentation across ethnic groups highlight the need to clarify how genetic and sociocultural factors interact with brain resilience and neuromodulatory system health[101].

Finally, the proposed *neuromodulatory fragility hypothesis* must address the question of why AD appears so human-specific, despite neuromodulatory systems being relatively well conserved across species. Non-human primates do develop A β pathology, but tau burden diminishes rapidly with increasing phylogenetic distance from humans[102]. Viewed through the lens of the *neuromodulatory fragility hypothesis*, this pattern suggests we should look closely at species differences in these systems. Many mammals express neuromelanin in monoaminergic nuclei (e.g. locus coeruleus, substantia nigra) but typically at much lower levels than humans[103]. Even across primates, neuromelanin content is greater in species more closely-related to us[103]. An striking exception, in terms of both the expression of AD-like pathology and neuromelanin can be seen in certain toothed whales (odontocetes)[104,105]. In some odontocetes, investigators have reported human-like co-occurrence of A β plaques and tau pathology[104] as well as neuromelanin in the locus coeruleus with ultrastructural features remarkably similar to humans[105]. Although direct quantitative comparisons across primates and odontocetes are still lacking, this apparent qualitative correlation between neuromelanin and AD-like pathology raises the hypothesis that neuromelanin burden may serve as a cross-species marker of cumulative neuromodulatory strain, which facilitates the emergence of AD.

The origin of this putative species-specific neuromodulatory strain remains unclear. One possibility is that a dramatically expanded neocortex provides unusually large target fields that must be modulated by relatively small populations of neuromodulatory cells. Indeed, human locus coeruleus and nucleus basalis of Meynert contain far fewer neurons relative to neocortical volume compared with non-human primates[106,107], a pattern that may hypothetically extend to odontocetes which have among the largest brain-to-body size ratios of any mammals[108]. A second plausible contributor is our unusually long post-reproductive lifespan, a feature shared almost exclusively by humans and toothed whales[109]. Consistent with this, odontocetes are also among the few non-human animals known to undergo menopause[110]. This convergence raises the possibility that menopause-related hormonal shifts may interact with neuromodulatory vulnerability, potentially helping to explain the higher incidence of AD in women[111] and fitting established links between oestrogen and cholinergic function[112].

Together, these observations hint that AD may emerge where evolutionarily conserved neuromodulatory systems are pushed beyond originally selected limits to modulate much broader regions across significantly longer lifetimes. Comparative studies of neuromodulatory systems across humans, non-human primates and odontocetes could provide powerful opportunities to test the proposed framework.

9. Conclusions

We have proposed a *neuromodulatory fragility hypothesis* for AD pathogenesis. This model offers a parsimonious account of how a single point of vulnerability (neuromodulatory projection neurons) can give rise to downstream hallmarks of AD, including the emergence of neurofibrillary tangles, A β plaques, neuroinflammation, cognitive-behavioural symptoms and dementia onset. The key insight of this model is that neuromodulatory system dysfunction is inherently tied to, and sufficient to explain, both tau hyperphosphorylation and increases in neocortical A β , the two hallmarks of AD. Given the inherent fragility of these volume transmission projection neurons in humans, it is no surprise through the lens of this framework that AD has such high global prevalence.

In this framework, genetic and environmental risk factors modulate AD risk through their cumulative effects on neuromodulatory resilience. The model predicts that strengthening these systems therefore represents the most effective strategy for preventing AD. Conversely, treatments that target downstream pathology are expected to offer only modest benefit once neuromodulatory dysfunction is established.

Our ideas and conclusions complement and expand upon recently proposed priorities for AD research from the Neuromodulatory Subcortical Systems Professional Interest Area of The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment[17]. By describing this hypothesis, we hope to further raise awareness of the importance of neuromodulatory subcortical systems in early AD, while providing a testable mechanistic explanation of pathogenesis that can help guide future research questions and the development of a new generation of effective disease-modifying therapies.

Funding: This work was funded by a NIH: National Institute of Aging R01 (RNS: AG068563), the Alzheimer's Association (RNS: AARG-22-927100), Fonds de Recherche du Québec - Santé (AW # 317644, RNS), a Jeanne Timmins Costello Postdoctoral Fellowship, McGill University (AW). Funding sources had no say in the writing of this manuscript, nor decision to submit this manuscript for publication.

Acknowledgments: We would like to thank the Laboratory of Brain and Cognition at the Montreal Neurological Institute for productive discussions and helpful feedback.

Disclosures: Authors have no competing interests to declare.

References

1. Duchesne, S. *et al.* A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories. *J Alzheimers Dis* **99**, 843–856 (2024).
2. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet* **396**, 413–446 (2020).
3. Jellinger, K. A. Pathobiological Subtypes of Alzheimer Disease. *Dement Geriatr Cogn Disord* **49**, 321–333 (2020).
4. Vogel, J. W. *et al.* Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nature Medicine* 1–11 (2021) doi:10.1038/s41591-021-01309-6.
5. Braak, H. & Braak, E. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging* **16**, 271278 (1995).
6. Thal, D. R., Rüb, U., Orantes, M. & Braak, H. Phases of A-Beta-deposition in the human brain and its relevance for the development of AD. *Neurology* **58**, 1791–1800 (2002).
7. Jack Jr., C. R. *et al.* Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia* **20**, 5143–5169 (2024).
8. Alzheimer's Association. 2024 Alzheimer's disease facts and figures. *Alzheimers Dement* **20**, 3708–3821 (2024).
9. Shanks, H. R. C. *et al.* p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. *Nat Med* **30**, 1761–1770 (2024).

10. Theofilas, P., Dunlop, S., Heinsen, H. & Grinberg, L. T. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimer's disease pathogenesis. *J Alzheimers Dis* **46**, 17–34 (2015).
11. Kampmann, M. Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases. *Nat. Rev. Neurosci.* 1–21 (2024) doi:10.1038/s41583-024-00806-0.
12. Mattson, M. P. & Arumugam, T. V. Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. *Cell Metabolism* **27**, 1176–1199 (2018).
13. Saxena, S. & Caroni, P. Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration. *Neuron* **71**, 35–48 (2011).
14. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine* **8**, 595–608 (2016).
15. Shine, J. M. *et al.* Human cognition involves the dynamic integration of neural activity and neuromodulatory systems. *Nat Neurosci* **22**, 289–296 (2019).
16. Shine, J. M. Neuromodulatory Influences on Integration and Segregation in the Brain. *Trends in Cognitive Sciences* **23**, 572–583 (2019).
17. Ehrenberg, A. J. *et al.* Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. *Alzheimer's & Dementia* <https://doi.org/10.1002/alz.12937> (2023) doi:10.1002/alz.12937.
18. Mather, M. & Harley, C. W. The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain. *Trends in Cognitive Sciences* **20**, 214–226 (2016).
19. Picciotto, M. R., Higley, M. J. & Mineur, Y. S. Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior. *Neuron* **76**, 116–129 (2012).
20. Pignatelli, M. & Bonci, A. Role of Dopamine Neurons in Reward and Aversion: A Synaptic Plasticity Perspective. *Neuron* **86**, 1145–1157 (2015).
21. Sakurai, T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* **8**, 171–181 (2007).
22. Hornung, J.-P. The human raphe nuclei and the serotonergic system. *Journal of Chemical Neuroanatomy* **26**, 331–343 (2003).
23. Özçete, Ö. D., Banerjee, A. & Kaeser, P. S. Mechanisms of neuromodulatory volume transmission. *Mol Psychiatry* **29**, 3680–3693 (2024).
24. Wu, H., Williams, J. & Nathans, J. Complete morphologies of basal forebrain cholinergic neurons in the mouse. *eLife* **3**, e02444 (2014).
25. Aransay, A., Rodríguez-López, C., García-Amado, M., Clascá, F. & Prensa, L. Long-range projection neurons of the mouse ventral tegmental area: a single-cell axon tracing analysis. *Front. Neuroanat.* **9**, (2015).
26. Wu, Y.-M., Hung, W.-C., Chang, Y., Min, M.-Y. & Yang, H.-W. Axon collateral pattern of a sparse locus coeruleus norepinephrine neuron in mouse cerebral cortex. 2025.02.04.636453 Preprint at <https://doi.org/10.1101/2025.02.04.636453> (2025).
27. Trillo, L. *et al.* Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. *Neuroscience & Biobehavioral Reviews* **37**, 1363–1379 (2013).
28. Giguère, N. *et al.* Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. *PLOS Genetics* **15**, e1008352 (2019).
29. Aston-Jones, G. & Cohen, J. D. AN INTEGRATIVE THEORY OF LOCUS COERULEUS-NOREPINEPHRINE FUNCTION: Adaptive Gain and Optimal Performance. *Annu. Rev. Neurosci.* **28**, 403–450 (2005).
30. Grace, A. A. & Bunney, B. S. The control of firing pattern in nigral dopamine neurons: single spike firing. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **4**, 2866–2876 (1984).
31. Allers, K. A. & Sharp, T. Neurochemical and anatomical identification of fast- and slow-firing neurones in the rat dorsal raphe nucleus using juxtacellular labelling methods in vivo. *Neuroscience* **122**, 193–204 (2003).
32. Ananth, M. R., Rajebhosale, P., Kim, R., Talmage, D. A. & Role, L. W. Basal forebrain cholinergic signalling: development, connectivity and roles in cognition. *Nat Rev Neurosci* **24**, 233–251 (2023).
33. Braak, H., Del Tredici, K., Schultz, C. & Braak, E. Vulnerability of Select Neuronal Types to Alzheimer's Disease. *Annals of the New York Academy of Sciences* **924**, 53–61 (2000).

34. Braak, H. & Del Tredici, K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. *Neurobiol Aging* **25**, 19–23 (2004).
35. Braak, H. & Braak, E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. *Acta Neuropathol* **92**, 197–201 (1996).
36. Pontzer, H. *et al.* Daily energy expenditure through the human life course. *Science* **373**, 808–812 (2021).
37. Matchett, B. J., Grinberg, L. T., Theofilas, P. & Murray, M. E. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease. *Acta Neuropathol* **141**, 631–650 (2021).
38. Iannitelli, A. F. & Weinshenker, D. Riddles in the dark: Decoding the relationship between neuromelanin and neurodegeneration in locus coeruleus neurons. *Neurosci Biobehav Rev* **152**, 105287 (2023).
39. Geula, C. *et al.* Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. *J Comp Neurol* **455**, 249–259 (2003).
40. Troutwine, B. R., Hamid, L., Lysaker, C. R., Strobe, T. A. & Wilkins, H. M. Apolipoprotein E and Alzheimer's disease. *Acta Pharmaceutica Sinica B* **12**, 496–510 (2022).
41. Blanchard, J. W. *et al.* APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. *Nature* **611**, 769–779 (2022).
42. Carandini, T., Cercignani, M., Galimberti, D., Scarpini, E. & Bozzali, M. The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems? *Brain, Behavior, and Immunity* **94**, 381–391 (2021).
43. Barbier, P. *et al.* Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects. *Front. Aging Neurosci.* **11**, (2019).
44. de Vos, K. J., Grierson, A. J., Ackerley, S. & Miller, C. C. J. Role of Axonal Transport in Neurodegenerative Diseases*. *Annual Review of Neuroscience* **31**, 151–173 (2008).
45. Wang, Z.-X., Tan, L. & Yu, J.-T. Axonal transport defects in Alzheimer's disease. *Mol Neurobiol* **51**, 1309–1321 (2015).
46. Scholz, T. & Mandelkow, E. Transport and diffusion of Tau protein in neurons. *Cell. Mol. Life Sci.* **71**, 3139–3150 (2014).
47. Hussain, L. S., Reddy, V. & Maani, C. V. Physiology, Noradrenergic Synapse. in *StatPearls* (StatPearls Publishing, Treasure Island (FL), 2025).
48. Chalermpananupap, T., Weinshenker, D. & Rorabaugh, J. M. Down but Not Out: The Consequences of Pretangle Tau in the Locus Coeruleus. *Neural Plast* **2017**, 7829507 (2017).
49. Braak, H. & Del Tredici, K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. *Brain* **138**, 2814–2833 (2015).
50. Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. *Journal of Neuropathology & Experimental Neurology* **70**, 960–969 (2011).
51. Geula, C., Nagykeri, N., Nicholas, A. & Wu, C.-K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. *J Neuropathol Exp Neurol* **67**, 309–318 (2008).
52. Satpati, A. *et al.* The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer's disease. 2024.03.06.583765 Preprint at <https://doi.org/10.1101/2024.03.06.583765> (2024).
53. Grinberg, L. T. *et al.* The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? *Neuropathology and Applied Neurobiology* **35**, 406–416 (2009).
54. Pierson, S. R. *et al.* Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's disease. *Mol Psychiatry* **30**, 532–546 (2025).
55. Cranston, A. L. *et al.* Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. *Brain Commun* **2**, fcaa033 (2020).
56. Wu, J. W. *et al.* Neuronal activity enhances tau propagation and tau pathology in vivo. *Nat Neurosci* **19**, 1085–1092 (2016).

57. Therriault, J. *et al.* Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease. *Science Translational Medicine* **14**, eabc8693 (2022).
58. Bueichekú, E. *et al.* Spatiotemporal patterns of locus coeruleus integrity predict cortical tau and cognition. *Nat Aging* **4**, 625–637 (2024).
59. Jacobs, H. I. L. *et al.* In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. *Sci. Transl. Med.* **13**, eabj2511 (2021).
60. Schmitz, T. W. & Spreng, R. N. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. *Nature Communications* **7**, 13249 (2016).
61. Fernández-Cabello, S. *et al.* Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. *Brain* **143**, 993–1009 (2020).
62. Yi, D. *et al.* Locus coeruleus tau is linked to successive cortical tau accumulation. *Alzheimer's & Dementia* **21**, e14426 (2025).
63. Roemer-Cassiano, S. N. *et al.* Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. *Sci Transl Med* **17**, eadp2564 (2025).
64. Salvadores, N., Gerónimo-Olvera, C. & Court, F. A. Axonal Degeneration in AD: The Contribution of A β and Tau. *Front Aging Neurosci* **12**, 581767 (2020).
65. Heneka, M. T. *et al.* Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. *Proceedings of the National Academy of Sciences* **107**, 6058–6063 (2010).
66. Gamage, R. *et al.* Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation. *Front. Cell. Neurosci.* **14**, (2020).
67. Schmitz, T. W., Soreq, H., Poirier, J. & Spreng, R. N. Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease. *J. Neurosci.* **40**, 1931–1942 (2020).
68. Wang, H. *et al.* Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation. *Nature* **421**, 384–388 (2003).
69. Ramos-Rodriguez, J. J. *et al.* Rapid β -amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. *J Neuropathol Exp Neurol* **72**, 272–285 (2013).
70. Chalermpananupap, T. *et al.* Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. *Alzheimers Res Ther* **5**, 21 (2013).
71. Gil-Bea, F. J. *et al.* Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice. *Neurobiol Dis* **48**, 439–446 (2012).
72. Frick, M. A. *et al.* Orexin/Hypocretin Modulates Neuroinflammatory Response to LPS in a Sex and Brain-Region Specific Manner in Young Rats. *J Neurochem* **169**, e70175 (2025).
73. Muresan, Z. & Muresan, V. Seeding Neuritic Plaques from the Distance: A Possible Role for Brainstem Neurons in the Development of Alzheimer's Disease Pathology. *Neurodegener Dis* **5**, 250–253 (2008).
74. Baker-Nigh, A. *et al.* Neuronal amyloid- β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. *Brain* **138**, 1722–1737 (2015).
75. Ni, Y. *et al.* Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. *Nat Med* **12**, 1390–1396 (2006).
76. Chen, Y. *et al.* $\alpha(2A)$ adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. *Proc Natl Acad Sci U S A* **111**, 17296–17301 (2014).
77. Busche, M. A. *et al.* Critical role of soluble amyloid- β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences* **109**, 8740–8745 (2012).
78. Ossenkoppele, R. *et al.* Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nature Medicine* **28**, 2381 (2022).
79. La Joie, R. *et al.* Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. *Sci Transl Med* **12**, eaau5732 (2020).
80. Bloom, G. S. Amyloid- β and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis. *JAMA Neurol* **71**, 505–508 (2014).
81. Busche, M. A. & Hyman, B. T. Synergy between amyloid- β and tau in Alzheimer's disease. *Nat Neurosci* **23**, 1183–1193 (2020).

82. Crary, J. F. *et al.* Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* **128**, 755–766 (2014).
83. Lee, W. J. *et al.* Regional A β -tau interactions promote onset and acceleration of Alzheimer's disease tau spreading. *Neuron* **110**, 1932–1943.e5 (2022).
84. Vogel, J. W. *et al.* Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight. *Nat. Rev. Neurosci.* **24**, 620–639 (2023).
85. Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. *Nat Rev Drug Discov* **21**, 306–318 (2022).
86. Braak, H. & Del Tredici, K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid- β formation. *Neurobiology of Aging* **25**, 713–718 (2004).
87. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by A β 42 Fibrils. *Science* **293**, 1491–1495 (2001).
88. Bertram, L., Lill, C. M. & Tanzi, R. E. The Genetics of Alzheimer Disease: Back to the Future. *Neuron* **68**, 270–281 (2010).
89. Jacobs, H. I. L. *et al.* Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. *Alzheimer's & Dementia* **19**, 169–180 (2023).
90. Dahl, M. J. *et al.* Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease. *Neurobiology of Aging* **112**, 39–54 (2022).
91. He, B. *et al.* Association between basal forebrain volume and age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred. *Alzheimers Dement* **22**, e71052 (2025).
92. Teipel, S., Grazia, A., Dyrba, M., Grothe, M. J. & Pomara, N. Basal forebrain volume and metabolism in carriers of the Colombian mutation for autosomal dominant Alzheimer's disease. *Sci Rep* **14**, 11268 (2024).
93. Arai, H., Ichimiya, Y., Kosaka, K., Moroji, T. & Iizuka, R. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia. *Prog Neuropsychopharmacol Biol Psychiatry* **16**, 883–890 (1992).
94. Stern, Y., Barnes, C. A., Grady, C., Jones, R. N. & Raz, N. Brain Reserve, Cognitive Reserve, Compensation, and Maintenance: Operationalization, Validity, and Mechanisms of Cognitive Resilience. *Neurobiol Aging* **83**, 124–129 (2019).
95. Stella, F. *et al.* Neuropsychiatric symptoms in the prodromal stages of dementia. *Current Opinion in Psychiatry* **27**, 230 (2014).
96. Orlando, I. F., Shine, J. M., Robbins, T. W., Rowe, J. B. & O'Callaghan, C. Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing. *Neuroscience & Biobehavioral Reviews* **149**, 105167 (2023).
97. Engels-Domínguez, N. *et al.* State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities. *Neuroscience & Biobehavioral Reviews* **144**, 104998 (2023).
98. Wearn, A. *et al.* Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status. *Nat Commun* **15**, 4706 (2024).
99. Chakraborty, S. *et al.* Multimodal gradients of basal forebrain connectivity across the neocortex. *Nat Commun* **15**, 8990 (2024).
100. Wood Alexander, M. *et al.* The interplay between age at menopause and synaptic integrity on Alzheimer's disease risk in women. *Science Advances* **11**, eadt0757 (2025).
101. Tang, M.-X. *et al.* Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. *Neurology* **56**, 49–56 (2001).
102. Toussaint, C., Bézard, E., Lemoine, M. & Planche, V. The biological scaling of Alzheimer's disease neuropathological changes across primate species. *Alzheimers Res Ther* **17**, 242 (2025).
103. Marsden, C. D. Pigmentation in the nucleus substantiae nigrae of mammals. *J Anat* **95**, 256–261 (1961).
104. Vacher, M. C. *et al.* Alzheimer's disease-like neuropathology in three species of oceanic dolphin. *Eur J Neurosci* **57**, 1161–1179 (2023).
105. Sacchini, S. *et al.* Toothed Whales Have Black Neurons in the Blue Spot. *Vet Sci* **9**, 525 (2022).
106. Sharma, Y. *et al.* Comparative anatomy of the locus coeruleus in humans and nonhuman primates. *J Comp Neurol* **518**, 963–971 (2010).

107. Raghanti, M. A. *et al.* Comparative analysis of the nucleus basalis of Meynert among primates. *Neuroscience* **184**, 1–15 (2011).
108. Worthy, G. A. J. & Hickie, J. P. Relative Brain Size in Marine Mammals. *The American Naturalist* **128**, 445–459 (1986).
109. Gunn-Moore, D., Kaidanovich-Beilin, O., Iradi, M. C. G., Gunn-Moore, F. & Lovestone, S. Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging. *Alzheimer's & Dementia* **14**, 195–204 (2018).
110. Ellis, S., Franks, D. W., Nielsen, M. L. K., Weiss, M. N. & Croft, D. P. The evolution of menopause in toothed whales. *Nature* **627**, 579–585 (2024).
111. Chêne, G. *et al.* Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimer's & Dementia* **11**, 310–320 (2015).
112. Newhouse, P. & Dumas, J. Estrogen-Cholinergic Interactions: Implications for Cognitive Aging. *Horm Behav* **74**, 173–185 (2015).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.